ClinVar Genomic variation as it relates to human health
NM_000094.4(COL7A1):c.6127G>A (p.Gly2043Arg)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000094.4(COL7A1):c.6127G>A (p.Gly2043Arg)
Variation ID: 17438 Accession: VCV000017438.39
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 3p21.31 3: 48575392 (GRCh38) [ NCBI UCSC ] 3: 48612825 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 4, 2013 Oct 8, 2024 Jun 24, 2023 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000094.4:c.6127G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000085.1:p.Gly2043Arg missense NC_000003.12:g.48575392C>T NC_000003.11:g.48612825C>T NG_007065.1:g.24861G>A LRG_286:g.24861G>A LRG_286t1:c.6127G>A LRG_286p1:p.Gly2043Arg Q02388:p.Gly2043Arg - Protein change
- G2043R
- Other names
- -
- Canonical SPDI
- NC_000003.12:48575391:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
- -
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
COL7A1 | - | - |
GRCh38 GRCh37 |
5221 | 5253 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (6) |
criteria provided, multiple submitters, no conflicts
|
Mar 14, 2022 | RCV000018988.34 | |
Pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Jun 24, 2023 | RCV000414315.14 | |
Pathogenic (1) |
criteria provided, single submitter
|
Sep 4, 2019 | RCV001192885.4 | |
Pathogenic (1) |
criteria provided, single submitter
|
Oct 19, 2018 | RCV001352763.3 | |
COL7A1-related disorder
|
Pathogenic (1) |
no assertion criteria provided
|
Aug 19, 2024 | RCV003924843.2 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Oct 19, 2018)
|
criteria provided, single submitter
Method: research
|
Dystrophic epidermolysis bullosa
Affected status: yes
Allele origin:
de novo,
germline
|
Biomedical Innovation Departament, CIEMAT
Accession: SCV001547345.1
First in ClinVar: Mar 28, 2021 Last updated: Mar 28, 2021 |
Observation 1:
Number of individuals with the variant: 4
Observation 2:
Number of individuals with the variant: 5
|
|
Pathogenic
(Mar 14, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Generalized dominant dystrophic epidermolysis bullosa
Affected status: yes
Allele origin:
germline
|
Center for Research in Genodermatoses and Epidermolysis Bullosa, University of Buenos Aires
Accession: SCV002499388.1
First in ClinVar: Aug 29, 2022 Last updated: Aug 29, 2022 |
Number of individuals with the variant: 14
Zygosity: Single Heterozygote
Family history: yes
Secondary finding: no
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Generalized dominant dystrophic epidermolysis bullosa
(Autosomal dominant inheritance)
Affected status: yes
Allele origin:
germline
|
Neuberg Centre For Genomic Medicine, NCGM
Accession: SCV004100513.1
First in ClinVar: Nov 04, 2023 Last updated: Nov 04, 2023 |
Comment:
The missense variant p.G2043R in COL7A1 (NM_000094.4) is the most common recurrent variant in the autosomal dominant dystrophic epidermolysis bullosa (Christiano et al, Nishie et … (more)
The missense variant p.G2043R in COL7A1 (NM_000094.4) is the most common recurrent variant in the autosomal dominant dystrophic epidermolysis bullosa (Christiano et al, Nishie et al,Vahidnezhad et al). It has been reported to ClinVar as Pathogenic.The p.G2043R variant is novel (not in any individuals) in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes.The p.G2043R missense variant is predicted to be damaging by both SIFT and PolyPhen2.The glycine residue at codon 2043 of COL7A1 is conserved in all mammalian species. The nucleotide c.6127 in COL7A1 is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. (less)
Clinical Features:
Abnormal blistering of the skin (present) , Scarring (present) , Pruritus (present) , Pretibial dystrophic epidermolysis bullosa (present)
|
|
Pathogenic
(Jun 24, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV002245841.3
First in ClinVar: Mar 28, 2022 Last updated: Feb 14, 2024 |
Comment:
For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats … (more)
For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL7A1 are more frequently observed in individuals with disease than in the general population (PMID: 22058051). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL7A1 protein function. ClinVar contains an entry for this variant (Variation ID: 17438). This missense change has been observed in individual(s) with autosomal dominant dystrophic epidermolysis bullosa (PMID: 7861014). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 2043 of the COL7A1 protein (p.Gly2043Arg). (less)
|
|
Pathogenic
(Sep 04, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Pretibial epidermolysis bullosa
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV001361321.1
First in ClinVar: Jun 22, 2020 Last updated: Jun 22, 2020 |
Comment:
Variant summary: COL7A1 c.6127G>A (p.Gly2043Arg) results in a non-conservative amino acid change located in the Collagen triple helix repeat (IPR008160) of the encoded protein sequence. … (more)
Variant summary: COL7A1 c.6127G>A (p.Gly2043Arg) results in a non-conservative amino acid change located in the Collagen triple helix repeat (IPR008160) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 243,072 control chromosomes (gnomAD). c.6127G>A has been reported in the literature in multiple individuals affected with Dominant Dystrophic Epidermolysis Bullosa (eg. Christiano_1995, Nishie_2014, Vahidnezhad_2017). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, suggesting that the variant results in accumulation of collagen VII in the cytoplasm and increased susceptibility to enzymatic degradation (Nishie_2014). One other clinical diagnostic laboratory has submitted a clinical-significance assessment for this variant to ClinVar (evaluation after 2014) and cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. (less)
|
|
Pathogenic
(Mar 26, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Generalized dominant dystrophic epidermolysis bullosa
Affected status: yes
Allele origin:
germline
|
Institute of Human Genetics, University of Leipzig Medical Center
Accession: SCV001428812.1
First in ClinVar: Aug 16, 2020 Last updated: Aug 16, 2020 |
Number of individuals with the variant: 1
|
|
Pathogenic
(Aug 05, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000490499.4
First in ClinVar: Jan 09, 2017 Last updated: Mar 04, 2023 |
Comment:
One of the most common recurrent pathogenic variants identified in DDEB patients across all ethnic backgrounds (Nanda et al., 2018; Yenamandra et al., 2018; Chen … (more)
One of the most common recurrent pathogenic variants identified in DDEB patients across all ethnic backgrounds (Nanda et al., 2018; Yenamandra et al., 2018; Chen et al., 2020); Published functional studies demonstrate a damaging effect, as G2043R induces intracytoplasmic accumulation of pro-C7, which hampers secretion of C7 in a dominant-negative fashion (Nishie et al., 2014); Located in the highly conserved Gly-X-Y repeat of the collagenous domain; Glycine substitution variants in this region of the COLVII protein destabilize the collagen triple helix resulting in skin fragility due to poor anchoring of the basement membrane to the underlying dermis (Pfendner and Lucky, 2018); Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24794830, 7861014, 28830826, 21448560, 9892921, 11260189, 9856843, 10951471, 32946877, 32506551, 31604626, 30011071, 29963685, 32484238, 9412818, 33274474) (less)
|
|
Pathogenic
(Oct 01, 1998)
|
no assertion criteria provided
Method: literature only
|
EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000039275.1
First in ClinVar: Apr 04, 2013 Last updated: Apr 04, 2013 |
Comment on evidence:
In a Hispanic-Mexican woman with the Pasini type of dominant epidermolysis bullosa dystrophica (131750), Mellerio et al. (1998) identified a heterozygous 6127G-A transition in exon … (more)
In a Hispanic-Mexican woman with the Pasini type of dominant epidermolysis bullosa dystrophica (131750), Mellerio et al. (1998) identified a heterozygous 6127G-A transition in exon 73 of the COL7A1 gene, resulting in a gly2043-to-arg (G2043R) substitution. The same mutation was found in 3 affected individuals from an unrelated Scottish family with dominant epidermolysis bullosa dystrophica. Although both families had some clinical features of the Pasini type, there was considerable interfamilial and intrafamilial variability. The mutation had previously been identified in 3 other families with dominant DEB, 1 Italian, 1 Hungarian, and 1 Norwegian. (less)
|
|
Pathogenic
(Aug 19, 2024)
|
no assertion criteria provided
Method: clinical testing
|
COL7A1-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004752009.2
First in ClinVar: Mar 16, 2024 Last updated: Oct 08, 2024 |
Comment:
The COL7A1 c.6127G>A variant is predicted to result in the amino acid substitution p.Gly2043Arg. This variant has been previously reported in the heterozygous state in … (more)
The COL7A1 c.6127G>A variant is predicted to result in the amino acid substitution p.Gly2043Arg. This variant has been previously reported in the heterozygous state in affected members of a family with autosomal dominant dystrophic epidermolysis bullosa (Christiano et al. 1995. PubMed ID: 7861014). It has also been reported as a recurrent de novo or inherited variant in many individuals with autosomal dominant dystrophic epidermolysis bullosa (Mellerio et al. 1998. PubMed ID: 9892921; Rouan et al. 1998. PubMed ID: 9856843; Wessagowit et al. 2001. PubMed ID: 11260189; Table S1, Almaani et al. 2011. PubMed ID: 21448560; Nishie et al. 2014. PubMed ID: 24794830; Supplementary Table S1, Vahidnezhad et al. 2017. PubMed ID: 28830826; Yenamandra et al. 2018. PubMed ID: 29963685; Nanda et al. 2018. PubMed ID: 30011071; Table S3, Chen et al. 2020. PubMed ID: 32484238). Furthermore, this variant resides in exon 73 and results in a glycine residue substitution. Glycine substitution variants in the triple helical domain (Gly-X-Y; especially in exons 73, 74, and 75) are predominant in autosomal dominant dystrophic epidermolysis bullosa (DDEB; https://www.ncbi.nlm.nih.gov/books/NBK1304/). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. (less)
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001742974.3 First in ClinVar: Jul 07, 2021 Last updated: Sep 08, 2021 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001952795.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021 |
|
|
Pathogenic
(Oct 30, 2023)
|
no assertion criteria provided
Method: clinical testing
|
Generalized dominant dystrophic epidermolysis bullosa
Affected status: yes
Allele origin:
germline
|
Zotz-Klimas Genetics Lab, MVZ Zotz Klimas
Accession: SCV004099442.1
First in ClinVar: Nov 04, 2023 Last updated: Nov 04, 2023 |
|
|
not provided
(-)
|
no classification provided
Method: literature only
|
Generalized dominant dystrophic epidermolysis bullosa
Affected status: unknown
Allele origin:
germline
|
GeneReviews
Accession: SCV004023210.1
First in ClinVar: Aug 05, 2023 Last updated: Aug 05, 2023 |
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Analysis of COL7A1 pathogenic variants in a large cohort of dystrophic epidermolysis bullosa patients from Argentina reveals a new genotype-phenotype correlation. | Natale MI | American journal of medical genetics. Part A | 2022 | PMID: 35979658 |
Dystrophic Epidermolysis Bullosa. | Adam MP | - | 2018 | PMID: 20301481 |
Multigene Next-Generation Sequencing Panel Identifies Pathogenic Variants in Patients with Unknown Subtype of Epidermolysis Bullosa: Subclassification with Prognostic Implications. | Vahidnezhad H | The Journal of investigative dermatology | 2017 | PMID: 28830826 |
A recurrent 'hot spot' glycine substitution mutation, G2043R in COL7A1, induces dominant dystrophic epidermolysis bullosa associated with intracytoplasmic accumulation of pro-collagen VII. | Nishie W | Journal of dermatological science | 2014 | PMID: 24794830 |
The COL7A1 mutation database. | Wertheim-Tysarowska K | Human mutation | 2012 | PMID: 22058051 |
Collagen structure and stability. | Shoulders MD | Annual review of biochemistry | 2009 | PMID: 19344236 |
A recurrent glycine substitution mutation, G2043R, in the type VII collagen gene (COL7A1) in dominant dystrophic epidermolysis bullosa. | Mellerio JE | The British journal of dermatology | 1998 | PMID: 9892921 |
A glycine-to-arginine substitution in the triple-helical domain of type VII collagen in a family with dominant dystrophic epidermolysis bullosa. | Christiano AM | The Journal of investigative dermatology | 1995 | PMID: 7861014 |
Crystal and molecular structure of a collagen-like peptide at 1.9 A resolution. | Bella J | Science (New York, N.Y.) | 1994 | PMID: 7695699 |
Characterization of collagen-like peptides containing interruptions in the repeating Gly-X-Y sequence. | Long CG | Biochemistry | 1993 | PMID: 8218237 |
Text-mined citations for rs121912836 ...
HelpRecord last updated Oct 13, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.